Drug Profile

Research programme: antimalarial therapeutics - Medicines for Malaria Venture/Takeda/University of Melbourne

Alternative Names: ELQ-300

Latest Information Update: 28 Apr 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medicines for Malaria Venture; Takeda
Developer Medicines for Malaria Venture; Takeda; University of Melbourne
Class Ethers; Quinolones; Small molecules
Mechanism of Action Electron transport complex III inhibitors; Proteasome inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Apr 2021 No recent reports of development identified for research development in Malaria in Switzerland (PO)
28 Apr 2019 No recent reports of development identified for research development in Malaria in Japan (PO)
30 Mar 2017 Antimalarial therapeutics are still in research development stage for Malaria in Japan

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com